We present new advances in blood-based biomarkers at CTAD 2025

The Barcelonaβeta Brain Research Center (BBRC) took part in the 18th edition of the Clinical Trials on Alzheimer’s Disease (CTAD) conference, held from 1 to 4 December in San Diego (USA), dedicated to clinical trials in Alzheimer’s disease. The centre was represented by Dr Gemma Salvadó, principal investigator of the neuroimaging group, who delivered an oral presentation on 2 December.

Her talk, entitled “Biological staging of Alzheimer's disease using blood-based biomarkers”, outlined how blood-based biomarkers can be used to define more precisely the biological stage of Alzheimer’s disease. This approach, which is rapidly expanding in the field of clinical trials, opens up new opportunities to improve early detection, monitor disease progression and optimise participant selection in therapeutic studies.

Dr Salvadó’s participation adds to those of the BBRC in previous editions of the conference, consolidating the centre’s continued presence in a key forum in the field of Alzheimer’s. This year, CTAD sought to highlight the rapid advances that are transforming the diagnosis and treatment of Alzheimer’s disease. Our participation reinforces the BBRC’s commitment to excellence in research aimed at improving early detection and accelerating the development of new therapeutic strategies.
 

More information about CTAD 2025.